Global Cancer Vaccines Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. North America has the largest share of the overall vaccines and specifically cancer vaccines market. This is followed by Europe and Asia. North America and Europe are expected to grow at a steady pace in the years to come. However, India and China are expected to see a boost in demand over the next 10 years, owing to their ageing populations and the prevalence of various infectious diseases.
“Global Cancer Vaccines Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various vaccines being developed for the treatment of multiple cancers. Research report covers all the ongoing vaccines being developed in various development phases. Each vaccine profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each vaccine profile in development phase enables the reader to identify and understand the Cell Therapy associated with the various diseases.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the cancer vaccine market based upon development process. Following parameters for each vaccine profile in development phase are covered in “Global Cancer Vaccines Pipeline Analysis” research report:
Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. North America has the largest share of the overall vaccines and specifically cancer vaccines market. This is followed by Europe and Asia. North America and Europe are expected to grow at a steady pace in the years to come. However, India and China are expected to see a boost in demand over the next 10 years, owing to their ageing populations and the prevalence of various infectious diseases.
“Global Cancer Vaccines Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various vaccines being developed for the treatment of multiple cancers. Research report covers all the ongoing vaccines being developed in various development phases. Each vaccine profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each vaccine profile in development phase enables the reader to identify and understand the Cell Therapy associated with the various diseases.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the cancer vaccine market based upon development process. Following parameters for each vaccine profile in development phase are covered in “Global Cancer Vaccines Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 9
- Preclinical: 75
- Phase-I: 42
- Phase-I/II: 32
- Phase-II: 43
- Phase-II/III: 6
- Phase-III: 19
- Preregistration: 2
- Marketed: 12
1. GLOBAL CANCER VACCINES MARKET OVERVIEW
1.1 Market Overview
1.2 Regional Market Analysis
1.3 Recent Trends
1.4 Future Market Direction
2. CANCER VACCINE DEVELOPMENT PHASE: RESEARCH
2.1 Overview
2.2 Vaccines Profiles in Development Phase
3. CANCER VACCINE DEVELOPMENT PHASE: PRECLINICAL
3.1 Overview
3.2 Vaccines Profiles in Development Phase
4. CANCER VACCINE DEVELOPMENT PHASE: PHASE-I
4.1 Overview
4.2 Vaccines Profiles in Development Phase
5. CANCER VACCINE DEVELOPMENT PHASE: PHASE-I/II
5.1 Overview
5.2 Vaccines Profiles in Development Phase
6. CANCER VACCINE DEVELOPMENT PHASE: PHASE-II
6.1 Overview
6.2 Vaccines Profiles in Development Phase
7. CANCER VACCINE DEVELOPMENT PHASE: PHASE-II/III
7.1 Overview
7.2 Vaccines Profiles in Development Phase
8. CANCER VACCINE DEVELOPMENT PHASE: PHASE-III
8.1 Overview
8.2 Vaccines Profiles in Development Phase
9. CANCER VACCINE DEVELOPMENT PHASE: PREREGISTRATION
9.1 Overview
9.2 Vaccines Profiles in Development Phase
10. CANCER VACCINE DEVELOPMENT PHASE: MARKETED
10.1 Overview
10.2 Vaccines Profiles in Development Phase
1.1 Market Overview
1.2 Regional Market Analysis
1.3 Recent Trends
1.4 Future Market Direction
2. CANCER VACCINE DEVELOPMENT PHASE: RESEARCH
2.1 Overview
2.2 Vaccines Profiles in Development Phase
3. CANCER VACCINE DEVELOPMENT PHASE: PRECLINICAL
3.1 Overview
3.2 Vaccines Profiles in Development Phase
4. CANCER VACCINE DEVELOPMENT PHASE: PHASE-I
4.1 Overview
4.2 Vaccines Profiles in Development Phase
5. CANCER VACCINE DEVELOPMENT PHASE: PHASE-I/II
5.1 Overview
5.2 Vaccines Profiles in Development Phase
6. CANCER VACCINE DEVELOPMENT PHASE: PHASE-II
6.1 Overview
6.2 Vaccines Profiles in Development Phase
7. CANCER VACCINE DEVELOPMENT PHASE: PHASE-II/III
7.1 Overview
7.2 Vaccines Profiles in Development Phase
8. CANCER VACCINE DEVELOPMENT PHASE: PHASE-III
8.1 Overview
8.2 Vaccines Profiles in Development Phase
9. CANCER VACCINE DEVELOPMENT PHASE: PREREGISTRATION
9.1 Overview
9.2 Vaccines Profiles in Development Phase
10. CANCER VACCINE DEVELOPMENT PHASE: MARKETED
10.1 Overview
10.2 Vaccines Profiles in Development Phase
